Global Regulators Agree On Acceptable Trial Endpoints For COVID-19 Treatments
International regulators have agreed on primary endpoints that would be suitable for assessing the clinical benefit of an investigational therapeutic for COVID-19 and support regulatory approval.
You may also be interested in...
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.